Last reviewed · How we verify
NCT05352542
GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma
Phase 1 trial testing GPC3 Targeting CART Cells in Advanced Hepatocellular Carcinoma in 10 participants. Terminated before completion.
31 July 2024
Quick facts
| Lead sponsor | jianming xu |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 19 May 2022 |
| Primary completion | 31 July 2024 |
| Estimated completion | 31 July 2024 |
| Sites | 2 locations across China |
Drugs / interventions tested
- GPC3 Targeting CART Cells — full drug profile →
Conditions studied
- Advanced Hepatocellular Carcinoma — all drugs for Advanced Hepatocellular Carcinoma →
Sponsor
jianming xu — full company profile →
Who can join
Adults 18 to 75, any sex, with Advanced Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Phase I Clinical Trial for Evaluating the Safety, Tolerance and Efficacy of GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting Glypican-3 for Liver Cancer Therapy: Clinical Applications and Detection Methods.
Zhang J, Li R, Tan X, Wang C. · · 2025 · cited 9× · PMID 40862283 · DOI 10.14218/jcth.2025.00099 -
Targeting glypican-3 as a new frontier in liver cancer therapy.
Wu CS, Lee TY, Chao HW. · · 2025 · cited 5× · PMID 41024885 · DOI 10.4254/wjh.v17.i9.107671 -
Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma.
Liang L, Wang X, Huang S, Chen Y, et al · · 2023 · cited 4× · PMID 36936932 · DOI 10.3389/fimmu.2023.1046771 -
Cancer stem cells in hepatocellular carcinoma: therapy resistance and emerging treatments.
Yadav DK, Yadav RK, Singh A, Huang Y, et al · · 2025 · PMID 41438763 · DOI 10.3389/fimmu.2025.1704868 -
Magnetic Resonance Imaging Using a Chimeric Anti-Glypican-3 Antibody Conjugated with Gadolinium Selectively Detects Glypican-3-Positive Hepatocellular Carcinoma In Vitro and In Vivo.
Liu Y, Tan M, Chua MS, So S. · · 2025 · PMID 41154412 · DOI 10.3390/cancers17203357
Verify or expand the search:
- PubMed search for NCT05352542
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Hepatocellular Carcinoma
Currently open trials in the same condition.
- NCT07166406 — Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO- · Phase 3 · recruiting
- NCT07174570 — Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer · Phase 2 · recruiting
- NCT07227012 — Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatmen · Phase 1, PHASE2 · recruiting
- NCT06811116 — Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metasta · Phase 1, PHASE2 · recruiting
- NCT06789848 — Ligufalimab and Cadonilimab in Advanced Liver Cancers · Phase 2 · recruiting
Other jianming xu trials
Trials by the same sponsor.
- NCT06946745 — Exploration of the Dynamic Changes and Mechanisms of the Immune Microenvironment in Advanced Colorectal Cancer Treated W · recruiting
- NCT05583201 — NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors · EARLY_PHASE1 · recruiting
- NCT05382377 — NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05352542 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by jianming xu
- Last refreshed: 9 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05352542.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing